XTL Biopharmaceuticals Ltd. announced that Robert Fox, MD and Simon Bowman, MD, have joined the company's clinical advisory board to help guide a planned Phase II trial to evaluate the company's investigational drug, hCDR1, for the treatment of Sjögren's syndrome (SS). Dr. Robert Fox, Chief of the Rheumatology Clinic at the Scripps-Ximed Medical Group at Scripps Memorial Hospital in La Jolla, CA, specializes in the pathogenesis and treatment of Sjögren's syndrome. He has been involved in studies of therapies to treat Sjögren's syndrome for more than 15 years, including writing clinical protocols for pivotal trials. He has edited a number of journals and pursued research as a principal investigator in multicenter clinical trials and his own NIH-funded research programs. Additionally, Dr. Fox serves as a member of the American College of Rheumatology'sAdvisory Board for Sjögren's Syndrome as well as the Advisory Board for the National Sjögren'sSyndrome Foundation. Professor Simon Bowman has been a consultant rheumatologist for over 15 years at the Queen Elizabeth Hospital in Birmingham. He is a Fellow at the Royal College of Physicians; a past President of the British Sjögren's Syndrome Association, member of the Sjögren's Syndrome Foundation of America and past President of the British Society for Rheumatology.